PubMed Journals Articles About "Indiana Blood And Marrow Transplantation" RSS

01:42 EST 18th December 2017 | BioPortfolio

Indiana Blood And Marrow Transplantation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Indiana Blood And Marrow Transplantation articles that have been published worldwide.

More Information about "Indiana Blood And Marrow Transplantation" on BioPortfolio

We have published hundreds of Indiana Blood And Marrow Transplantation news stories on BioPortfolio along with dozens of Indiana Blood And Marrow Transplantation Clinical Trials and PubMed Articles about Indiana Blood And Marrow Transplantation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Indiana Blood And Marrow Transplantation Companies in our database. You can also find out about relevant Indiana Blood And Marrow Transplantation Drugs and Medications on this site too.

Showing "Indiana Blood Marrow Transplantation" PubMed Articles 1–25 of 11,000+

A Time to Event Ratio to Predict Outcome in Patients with Aml Undergoing Allogeneic Hematopoietic Cell Transplantation?

"If All You Have is a Hammer …": Transplants for Myelodysplastic Syndrome (MDS) after Hypomethylating Agents (HMA) Fail.

Is It All About Age or Personalized Haplo HCT for Elderly?

Lessons Learned From Early Experiences with Vedolizumab for Steroid Refractory Acute Graft Versus Host Disease with Gastrointestinal Involvement.


Hematopoietic Stem Cell Transplant for a New Primary Immunodeficiency Disorder: a Voyage Where No Transplant Physician Has Gone before.

Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database.

Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukaemia.

Several studies have reported an impact of the adult haematopoietic stem cells donors cytomegalovirus (CMV) serostatus on allogeneic haematopoietic cell transplantation (HCT) outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analysed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year non-relapse mortality (NRM) of single-unit CBU transplantation for a...

Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation.

In this retrospective analysis using the Transplant Registry Unified Management Program, we identified 145 patients with human herpesvirus (HHV)-6 encephalitis among 6593 recipients. The cumulative incidences of HHV-6 encephalitis at 100 days after transplantation in all patients, recipients of bone marrow or PBSCs and recipients of cord blood were 2.3%, 1.6% and 5.0%, respectively. Risk factors identified in multivariate analysis were male sex, type of transplanted cells (relative risk in cord blood transp...

Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.

Idiopathic pneumonia syndrome (IPS) is a non-infectious pulmonary complication after hematopoietic cell transplantation (HCT) and is difficult to diagnose. We evaluated six candidate proteins in plasma samples at day 7 after HCT and at onset of IPS from 41 IPS cases to identify potential IPS diagnostic or prognostic biomarkers. Samples at similar times from 162 HCT recipients without documented infections and 37 HCT recipients with respiratory viral pneumonia served as controls. In multivariable models, a c...

HLA coding in ProMISe: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC).

As part of the 7th Annual francophone workshop series on the harmonization of clinical practices in allogeneic stem cell transplantation held in Lille in September 2016, our workgroup discussed how transplant centers might follow a collective approach to coding data. This was done mainly by analyzing the study results found in the literature that do not provide clear answers. In addition, we discuss practical ways of coding for both donor and recipient HLA typing in the European bone marrow transplantation ...

Unrelated cord blood transplantation in aplastic anemia: is anti-thymocyte globulin indispensable for conditioning?

Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.

Few reports have focused on adolescent and young adult (AYAs) patients with acute myeloid leukemia (AML) treated with hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis based on data obtained from a Japanese nationwide registration database to compare HSCT outcomes in AYA patients with AML with those in children with AML. An analysis of the 2,973 patients with de novo AML who received allogeneic HSCT from 1990 to 2013 showed inferior 5-year overall survival (OS) (54% vs. 5...

Risk Factors for Subsequent Central Nervous System (CNS) Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant (HCT): a Study From the Center for International Blood and Marrow Transplant Research (CIBMTR).

Survivors of Hematopoietic cell transplantation (HCT) are at risk of subsequent solid tumors, including central nervous system (CNS) tumors. The risk of CNS tumors post HCT in pediatric HCT recipients is not known. We evaluated the incidence and risk factors for CNS tumors in pediatric recipients of allogeneic HCT reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1976 and 2008. A case control design was used. There were no CNS tumors in the non-malignant cohort (...

Preoperative autologous blood donation in healthy bone marrow donors contributes to pre-procedure anemia.

Chimerism analysis after hematopoietic cell transplantation: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC).

Chimerism analysis is an important step for the patient follow-up after hematopoietic stem cell transplantation. It is used to quantify the donor and the recipient part of a cell population issued from blood or bone marrow sample. In addition to hemogram, this technique is necessary to appreciate the quality of engraftment. The aim of this article is to propose some recommendation about methods, result analysis and therapeutic decision in hematopoietic stem cell transplantation for malignant or non-malignan...

Umbilical Cord Blood Transplantation: Challenges and Future Directions.

Since the first successful allogeneic transplants performed in Seattle 50 years ago, the field of transplantation has evolved considerably, with improvements in human leukocyte antigen typing, patient selection, reduced intensity regimens, and graft-versus-host disease prophylaxis. A major breakthrough has been the availability of more donor options, first via the National Marrow Donor Program-Be the Match [Biol Blood Marrow Transplant 2008;14:2-7]. Then, in the 1990s, unrelated umbilical cord blood transpl...

A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics and Outcomes.

There are limited reports of central nervous system invasive fungal disease (CNS-IFD) in allogeneic stem cell transplantation (HSCT) recipient. We aimed to describe the clinical characteristics and the risk factors of CNS-IFD. We retrospectively reviewed the consecutive HSCT patients in Peking University Institute of Hematology during a 10-years period. A total of 29 patients were complicated with CNS-IFD. The median onset time of CNS-IFD was 173 (24-972) day after HSCT. The most frequent pathogen was asper...

Late effects of blood and marrow transplantation.

Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: a Multicenter Cohort Study.

Hematopoietic cell transplant (HCT) is associated with a pro-inflammatory, pro-coagulant environment which places recipients at increased risk of venous thromboembolism (VTE). While the incidence of VTE in adult HCT recipients has been extensively studied, similar data for children are lacking. We conducted a multicenter retrospective study to analyze the prevalence of VTE and associated risk factors in a large cohort of patients who underwent HCT at tertiary-care US children's hospitals.

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of HCT that belongs to a group of diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe SOS/VOD results in multi-organ dysfunction/failure with a mortality rate >80%. A timely d...

Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT).

High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for relapsed/refractory testicular germ cell tumor (GCT), but only few data have been reported in female patients with GCT. We conducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for Blood and Marrow Transplantation (EBMT).

Cellular Immunotherapy for Haematological Malignancies: Beyond Bone Marrow Transplant.

Immunotherapy has changed treatment practices for many haematological malignancies. Despite the current era of targeted therapy, chemotherapy remains the backbone of treatment for many haematological malignancies, especially in acute leukaemia, where relapse remains the major cause of mortality. Application of novel immunotherapies in haematology attempts to harness the killing power of the immune system against leukaemia and lymphoma. Cellular immunotherapy is evolving rapidly for high risk haematological ...

Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID.

Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High Dose Cyclophosphamide.

We studied the impact of HLA mismatching on the outcome of 318 consecutive patients who received an un-manipulated haploidentical bone marrow transplant, followed by post-transplant cyclophosphamide (PT-CY). The number of HLA mismatched antigens was tested for its impact on overall survival (OS) and non relapse mortality (NRM), whereas HLA mismatches in the graft versus host (GvH) direction were tested for prediction of GvHD and relapse; finally, we studied whether graft rejection correlated with the number...

Quick Search